Shopping Cart
- Remove All
- Your shopping cart is currently empty
Satraplatin (BMS182751) is an orally available antineoplastic platinum(IV) complex.Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $100 | In Stock | |
5 mg | $247 | In Stock | |
10 mg | $396 | In Stock | |
25 mg | $648 | In Stock | |
50 mg | $892 | In Stock | |
100 mg | $1,230 | In Stock |
Description | Satraplatin (BMS182751) is an orally available antineoplastic platinum(IV) complex.Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies. |
In vitro | KB-R cells did not show cross-resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB-R cells. There was no difference in the GSH levels between the KB and KB-R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB-R cells. KB-R cells contain enriched side population cells[1]. |
Cell Research | CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment[1]. |
Alias | JM216, BMY45594, BMS182751 |
Molecular Weight | 500.28 |
Formula | C10H22Cl2N2O4Pt |
Cas No. | 129580-63-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 33 mg/mL (65.96 mM), DMSO inactivates the activity of Satraplatin. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.